Compare · HELP vs NVO
HELP vs NVO
Side-by-side comparison of Cybin Inc. (HELP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HELP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 495.8x HELP ($449.4M).
- Over the past year, HELP is down 12.4% and NVO is down 21.8% - HELP leads by 9.4 points.
- HELP has been more active in the news (16 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 2 for HELP).
- Company
- Cybin Inc.
- Novo Nordisk A/S
- Price
- $7.25+2.98%
- $50.31-2.25%
- Market cap
- $449.4M
- $222.81B
- 1M return
- +69.00%
- +15.47%
- 1Y return
- -12.39%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 16
- 5
- Recent ratings
- 2
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HELP
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- SEC Form 6-K filed by Cybin Inc.
- SEC Form D filed by Cybin Inc.
- SEC Form D filed by Cybin Inc.
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- SEC Form 6-K filed by Cybin Inc.
- Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
- SEC Form 40-F filed by Cybin Inc.
- A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
- SEC Form 6-K filed by Cybin Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S